This paper reviews the research progress on AKR1B10 in liver, gastric, colorectal, pancreatic, oral, laryngeal, and bile duct cancers, which are digestive tumor diseases, and emphasizes that, except for the downregulation of AKR1B10 expression in GC and CRC, AKR1B10 is overexpressed in the rest of the solid tumors, and it thus has potential as a diagnostic and prognostic indicator in all of these solid tumors. Here, AKR1B10 is linked to gastric cancer.